Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS

Clinical trial NCT03855371 · UNKNOWN

Trial details

NCT number: NCT03855371
Sponsor: Ruijin Hospital
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

P53 Mutation Myeloid Malignancy MDS Aml

Start date: 2018-01-10
Primary completion: 2023-07-01
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.